Literature DB >> 21047916

Systems biology and genomics of breast cancer.

Charles M Perou1, Anne-Lise Børresen-Dale.   

Abstract

It is now accepted that breast cancer is not a single disease, but instead it is composed of a spectrum of tumor subtypes with distinct cellular origins, somatic changes, and etiologies. Gene expression profiling using DNA microarrays has contributed significantly to our understanding of the molecular heterogeneity of breast tumor formation, progression, and recurrence. For example, at least two clinical diagnostic assays exist (i.e., OncotypeDX RS and Mammaprint®) that are able to predict outcome in patients using patterns of gene expression and predetermined mathematical algorithms. In addition, a new molecular taxonomy based upon the inherent, or "intrinsic," biology of breast tumors has been developed; this taxonomy is called the "intrinsic subtypes of breast cancer," which now identifies five distinct tumor types and a normal breast-like group. Importantly, the intrinsic subtypes of breast cancer predict patient relapse, overall survival, and response to endocrine and chemotherapy regimens. Thus, most of the clinical behavior of a breast tumor is already written in its subtype profile. Here, we describe the discovery and basic biology of the intrinsic subtypes of breast cancer, and detail how this interacts with underlying genetic alternations, response to therapy, and the metastatic process.

Entities:  

Mesh:

Year:  2011        PMID: 21047916      PMCID: PMC3039533          DOI: 10.1101/cshperspect.a003293

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Biol        ISSN: 1943-0264            Impact factor:   10.005


  101 in total

1.  A molecular signature of metastasis in primary solid tumors.

Authors:  Sridhar Ramaswamy; Ken N Ross; Eric S Lander; Todd R Golub
Journal:  Nat Genet       Date:  2002-12-09       Impact factor: 38.330

2.  Mammary development meets cancer genomics.

Authors:  Aleix Prat; Charles M Perou
Journal:  Nat Med       Date:  2009-08       Impact factor: 53.440

3.  Genomic architecture characterizes tumor progression paths and fate in breast cancer patients.

Authors:  Hege G Russnes; Hans Kristian Moen Vollan; Ole Christian Lingjærde; Alexander Krasnitz; Pär Lundin; Bjørn Naume; Therese Sørlie; Elin Borgen; Inga H Rye; Anita Langerød; Suet-Feung Chin; Andrew E Teschendorff; Philip J Stephens; Susanne Månér; Ellen Schlichting; Lars O Baumbusch; Rolf Kåresen; Michael P Stratton; Michael Wigler; Carlos Caldas; Anders Zetterberg; James Hicks; Anne-Lise Børresen-Dale
Journal:  Sci Transl Med       Date:  2010-06-30       Impact factor: 17.956

4.  Prospective identification of tumorigenic breast cancer cells.

Authors:  Muhammad Al-Hajj; Max S Wicha; Adalberto Benito-Hernandez; Sean J Morrison; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

5.  A multigenic program mediating breast cancer metastasis to bone.

Authors:  Yibin Kang; Peter M Siegel; Weiping Shu; Maria Drobnjak; Sanna M Kakonen; Carlos Cordón-Cardo; Theresa A Guise; Joan Massagué
Journal:  Cancer Cell       Date:  2003-06       Impact factor: 31.743

6.  A gene-expression signature as a predictor of survival in breast cancer.

Authors:  Marc J van de Vijver; Yudong D He; Laura J van't Veer; Hongyue Dai; Augustinus A M Hart; Dorien W Voskuil; George J Schreiber; Johannes L Peterse; Chris Roberts; Matthew J Marton; Mark Parrish; Douwe Atsma; Anke Witteveen; Annuska Glas; Leonie Delahaye; Tony van der Velde; Harry Bartelink; Sjoerd Rodenhuis; Emiel T Rutgers; Stephen H Friend; René Bernards
Journal:  N Engl J Med       Date:  2002-12-19       Impact factor: 91.245

7.  Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.

Authors:  Elgene Lim; François Vaillant; Di Wu; Natasha C Forrest; Bhupinder Pal; Adam H Hart; Marie-Liesse Asselin-Labat; David E Gyorki; Teresa Ward; Audrey Partanen; Frank Feleppa; Lily I Huschtscha; Heather J Thorne; Stephen B Fox; Max Yan; Juliet D French; Melissa A Brown; Gordon K Smyth; Jane E Visvader; Geoffrey J Lindeman
Journal:  Nat Med       Date:  2009-08-02       Impact factor: 53.440

8.  CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages.

Authors:  David G DeNardo; Jairo B Barreto; Pauline Andreu; Lesley Vasquez; David Tawfik; Nikita Kolhatkar; Lisa M Coussens
Journal:  Cancer Cell       Date:  2009-08-04       Impact factor: 31.743

9.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.

Authors:  Aleix Prat; Joel S Parker; Olga Karginova; Cheng Fan; Chad Livasy; Jason I Herschkowitz; Xiaping He; Charles M Perou
Journal:  Breast Cancer Res       Date:  2010-09-02       Impact factor: 6.466

10.  Repeated observation of breast tumor subtypes in independent gene expression data sets.

Authors:  Therese Sorlie; Robert Tibshirani; Joel Parker; Trevor Hastie; J S Marron; Andrew Nobel; Shibing Deng; Hilde Johnsen; Robert Pesich; Stephanie Geisler; Janos Demeter; Charles M Perou; Per E Lønning; Patrick O Brown; Anne-Lise Børresen-Dale; David Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-26       Impact factor: 12.779

View more
  79 in total

1.  Lectin chromatography/mass spectrometry discovery workflow identifies putative biomarkers of aggressive breast cancers.

Authors:  Penelope M Drake; Birgit Schilling; Richard K Niles; Akraporn Prakobphol; Bensheng Li; Kwanyoung Jung; Wonryeon Cho; Miles Braten; Halina D Inerowicz; Katherine Williams; Matthew Albertolle; Jason M Held; Demetris Iacovides; Dylan J Sorensen; Obi L Griffith; Eric Johansen; Anna M Zawadzka; Michael P Cusack; Simon Allen; Matthew Gormley; Steven C Hall; H Ewa Witkowska; Joe W Gray; Fred Regnier; Bradford W Gibson; Susan J Fisher
Journal:  J Proteome Res       Date:  2012-03-13       Impact factor: 4.466

Review 2.  A review of the importance of immune responses in luminal B breast cancer.

Authors:  Delia J Nelson; Briony Clark; Kylie Munyard; Vincent Williams; David Groth; Jespal Gill; Henry Preston; Arlene Chan
Journal:  Oncoimmunology       Date:  2017-01-19       Impact factor: 8.110

3.  Chemotherapeutic Targeting of the Transforming Growth Factor-β Pathway in Breast Cancers.

Authors:  Yong-Hun Lee; William P Schiemann
Journal:  Breast Cancer Manag       Date:  2014

4.  Impact of tumor microenvironment and epithelial phenotypes on metabolism in breast cancer.

Authors:  Heather Ann Brauer; Liza Makowski; Katherine A Hoadley; Patricia Casbas-Hernandez; Lindsay J Lang; Erick Romàn-Pèrez; Monica D'Arcy; Alex J Freemerman; Charles M Perou; Melissa A Troester
Journal:  Clin Cancer Res       Date:  2012-12-12       Impact factor: 12.531

Review 5.  Implication of environmental estrogens on breast cancer treatment and progression.

Authors:  Thomas L Gonzalez; James M Rae; Justin A Colacino
Journal:  Toxicology       Date:  2019-03-30       Impact factor: 4.221

6.  Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer.

Authors:  Keli Xu; Jerry Usary; Philaretos C Kousis; Aleix Prat; Dong-Yu Wang; Jessica R Adams; Wei Wang; Amanda J Loch; Tao Deng; Wei Zhao; Robert Darrell Cardiff; Keejung Yoon; Nicholas Gaiano; Vicki Ling; Joseph Beyene; Eldad Zacksenhaus; Tom Gridley; Wey L Leong; Cynthia J Guidos; Charles M Perou; Sean E Egan
Journal:  Cancer Cell       Date:  2012-05-15       Impact factor: 31.743

7.  The olive oil phenolic (-)-oleocanthal modulates estrogen receptor expression in luminal breast cancer in vitro and in vivo and synergizes with tamoxifen treatment.

Authors:  Nehad M Ayoub; Abu Bakar Siddique; Hassan Y Ebrahim; Mohamed M Mohyeldin; Khalid A El Sayed
Journal:  Eur J Pharmacol       Date:  2017-06-15       Impact factor: 4.432

8.  Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer.

Authors:  Shubing Zhang; Wen-cheng Chung; Lucio Miele; Keli Xu
Journal:  Cancer Biol Ther       Date:  2014-02-20       Impact factor: 4.742

9.  Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).

Authors:  Begoña Martin-Castillo; Cristina Oliveras-Ferraros; Alejandro Vazquez-Martin; Silvia Cufí; José Manuel Moreno; Bruna Corominas-Faja; Ander Urruticoechea; Ángel G Martín; Eugeni López-Bonet; Javier A Menendez
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

10.  Benzimidazoles diminish ERE transcriptional activity and cell growth in breast cancer cells.

Authors:  Florastina Payton-Stewart; Syreeta L Tilghman; LaKeisha G Williams; Leyte L Winfield
Journal:  Biochem Biophys Res Commun       Date:  2014-07-02       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.